Do gastrointestinal side effects contribute meaningfully to tirzepatide-related weight loss? In this post hoc analysis of the SURMOUNT-1 to -4 trials, supported by AMR Clinical sites, researchers found that weight reduction occurred regardless of nausea, vomiting, or diarrhea. GI side effects were common but typically mild, and their contribution to weight loss was minimal based on mediation analyses.
Read this publication to explore:
- Rates of GI side effects across tirzepatide dose arms
- How weight loss compared for participants with vs without GI events
- Mediation analysis results on GI impact in weight outcomes